Endo Presents Data on the Perception and Measurement of Cellulite Severity at the American Society for Dermatologic Surgery (ASDS) Annual Meeting
One of the two abstract posters to be presented is titled "Assessing Cellulite Severity: Test-Retest Reliability of and Concordance between New Clinician Reported and Patient Reported Photonumeric Scales" and covers the 5-point photonumeric scales that measure cellulite severity according to the number and depth of dimples on the evaluated area. Results indicate that the CR-PCSS is a reliable tool for evaluating cellulite severity of the buttocks and thighs and correlates well with the Patient Reported Photonumeric Cellulite Severity Scale. This data was previously presented at the 2018
The second abstract poster, titled "Analysis of Potential Impact of Healthcare Provider Gender on Rating Cellulite Severity," evaluates the influence of gender on healthcare providers' perception of cellulite severity. The HCPs rated female cellulite severity by viewing a set of digital images that represented the range of cellulite severity on buttocks or thighs. The results indicate that the gender of a HCP does not appear to impact assessment of cellulite severity ratings.
"We are pleased that the data from these studies will be presented at the premier meeting for dermatologic surgeons," said Matthew Davis, M.D., R.Ph., Chief Medical Officer, Senior Vice President, Research and Development, Branded Pharmaceuticals of Endo Pharmaceuticals. "It is important that healthcare providers and their patients have a reliable tool for evaluating cellulite severity. We believe the 5-point photonumeric scales enable patients and the clinician treating their cellulite to be aligned during both the informed consent process prior to treatment, and post treatment when they are evaluating the outcomes."
Cellulite is a localized metabolic disorder of tissue under the skin that has been reported in 85 to 98 percent of post-pubertal females and affects women of all races and ethnicities[i] [ii]. The condition can involve the loss of elasticity or shrinking of collagen cords, called "septae," that attach the skin to the muscle layers below. When fat in cellulite-prone areas swells and expands, the septae tether the skin, which causes the surface dimpling characteristic of cellulite[iii]. Despite multiple therapeutic approaches for the attempted treatment of cellulite, there are no
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and Canadian securities legislation, including, but not limited to, the statements by Dr. Davis, and other statements regarding research and development outcomes, efficacy, adverse reactions, market and product potential and product availability. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties. Although Endo believes that these forward-looking statements and information are based upon reasonable assumptions and expectations, readers should not place undue reliance on them, or any other forward-looking statements or information in this news release. Investors should note that many factors, as more fully described in the documents filed by Endo with the Securities and Exchange Commission and with securities regulators in Canada on the System for Electronic Document Analysis and Retrieval, including under the caption "Risk Factors" in Endo's Form 10-K, Form 10-Q and Form 8-K filings, and as otherwise enumerated herein or therein, could affect Endo's future results and could cause Endo's actual results to differ materially from those expressed in forward-looking statements contained in this communication. The forward-looking statements in this press release are qualified by these risk factors.
[i] Avram, Cellulite: a review of its physiology and treatment,
[ii] Khan MH et al. Treatment of cellulite: Part I. Pathophysiology. J Am Acad Dermatol. 2010 Mar;62(3):361-70.
[iii] Querleux, Anatomy and physiology of subcutaneous adipose tissue by in vivo MRI and spectroscopy: Relationship with sex and presence of cellulite,
[iv] Wanner M et al. An evidence-based assessment of treatments for cellulite. J Drugs Dermatol. 2008 Apr;7(4):341-5.
View original content:http://www.prnewswire.com/news-releases/endo-presents-data-on-the-perception-and-measurement-of-cellulite-severity-at-the-american-society-for-dermatologic-surgery-asds-annual-meeting-300728834.html
Endo International plc - Media: Heather Zoumas-Lubeski, (484) 216-6829, Investors: Laure Park, (845) 364-4862